OBJECTIVES: This study examined HIV prevalence and risk behaviors among male injection drug users (IDUs) who have sex with men and among other male IDUs. METHODS: Male IDUs were interviewed and tested for HIV at a detoxification clinic during 1990 to 1994 and 1995 to 1999. Analyses compared male IDUs who do and do not have sex with men within and between periods. RESULTS: Initially, HIV seroprevalence and risk behaviors were higher among IDUs who have sex with men. Seroprevalence (initially 60.5% vs 48.3%) declined approximately 15% in both groups, remaining higher among those who have sex with men. Generally, injection prevalence, but not sexual risk behaviors, declined. CONCLUSIONS: Male IDUs who have sex with men are more likely to engage in higher-risk behaviors and to be HIV infected. Improved intervention approaches for male IDUs who have sex with men are needed.
OBJECTIVES: This study examined HIV prevalence and risk behaviors among male injection drug users (IDUs) who have sex with men and among other male IDUs. METHODS: Male IDUs were interviewed and tested for HIV at a detoxification clinic during 1990 to 1994 and 1995 to 1999. Analyses compared male IDUs who do and do not have sex with men within and between periods. RESULTS: Initially, HIV seroprevalence and risk behaviors were higher among IDUs who have sex with men. Seroprevalence (initially 60.5% vs 48.3%) declined approximately 15% in both groups, remaining higher among those who have sex with men. Generally, injection prevalence, but not sexual risk behaviors, declined. CONCLUSIONS: Male IDUs who have sex with men are more likely to engage in higher-risk behaviors and to be HIV infected. Improved intervention approaches for male IDUs who have sex with men are needed.
Authors: D C Des Jarlais; M Marmor; P Friedmann; S Titus; E Aviles; S Deren; L Torian; D Glebatis; C Murrill; E Monterroso; S R Friedman Journal: Am J Public Health Date: 2000-03 Impact factor: 9.308
Authors: S R Friedman; T F Chapman; T E Perlis; R Rockwell; D Paone; J L Sotheran; D C Des Jarlais Journal: J Acquir Immune Defic Syndr Date: 1999-09-01 Impact factor: 3.731
Authors: D C Des Jarlais; S R Friedman; T Perlis; T F Chapman; J L Sotheran; D Paone; E Monterroso; A Neaigus Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1999-01-01
Authors: F Rhodes; S Deren; M M Wood; M G Shedlin; R G Carlson; E Y Lambert; L M Kochems; M J Stark; R S Falck; L Wright-DeAgüero; B Weir; L Cottler; K M Rourke; R T Trotter Journal: AIDS Care Date: 1999-12
Authors: M Marmor; D C Des Jarlais; H Cohen; S R Friedman; S T Beatrice; N Dubin; W el-Sadr; D Mildvan; S Yancovitz; U Mathur Journal: AIDS Date: 1987-05 Impact factor: 4.177
Authors: H A Siegal; R G Carlson; R Falck; L Li; M A Forney; R C Rapp; K Baumgartner; W Myers; M Nelson Journal: Am J Public Health Date: 1991-12 Impact factor: 9.308
Authors: Don C Des Jarlais; Theresa Perlis; Kamyar Arasteh; Lucia V Torian; Sara Beatrice; Judith Milliken; Donna Mildvan; Stanley Yancovitz; Samuel R Friedman Journal: Am J Public Health Date: 2005-06-28 Impact factor: 9.308
Authors: J F G Monteiro; D J Escudero; C Weinreb; T Flanigan; S Galea; S R Friedman; B D L Marshall Journal: Epidemiol Infect Date: 2016-01-12 Impact factor: 2.451
Authors: Alex H Kral; Jennifer Lorvick; Daniel Ciccarone; Lynn Wenger; Lauren Gee; Alexis Martinez; Brian R Edlin Journal: J Urban Health Date: 2005-02-28 Impact factor: 3.671
Authors: Suzan M Walters; Bethany Coston; Alan Neaigus; Alexis V Rivera; Lila Starbuck; Valentina Ramirez; Kathleen H Reilly; Sarah L Braunstein Journal: Int J Drug Policy Date: 2020-02-21